In the News Nov. 30 – Dec. 1, 2017
Total Page：16
File Type：pdf, Size：1020Kb
From: ITNDaily Subject: Mount Sinai In The News - November 30 - December 1, 2017 Date: Friday, December 01, 2017 11:39:33 AM Attachments: ATT00002.txt In the News Nov. 30 – Dec. 1, 2017 Targeted Oncology – November 29 Ramon Parsons Awarded Outstanding Investigator Award From The National Cancer Institute Renowned scientist Ramon Parsons, MD, PhD, director of the Tisch Cancer Institute at Mount Sinai, professor and chair of oncological sciences at the Icahn School of Medicine at Mount Sinai, has been awarded an Outstanding Investigator Award from the National Cancer Institute. The award guarantees $6.7 million for seven years of research into the tumor-suppressing functions of the PTEN gene, which Dr. Parsons discovered. The award will be used to determine how the tumor-suppressing gene, PTEN, and its variant, PTEN-L, are regulated; to study tumors’ development and metabolism when the gene is inactivated; and to develop small molecule therapies that target tumor cells that have cancer-causing mutations in the PTEN gene. “Understanding PTEN could hold the key to helping patients with some of the most aggressive and the most treatment-resistant cancers, such as triple-negative breast cancer and prostate cancer,” said Dr. Parsons. - Ramon Parsons, MD, PhD, Director, The Tisch Cancer Institute at Mount Sinai, Professor, Chair, Oncological Sciences, Icahn School of Medicine at Mount Sinai Learn more: http://www.targetedonc.com/news/ramon-parsons-awarded-outstanding-investigator-award-from-the-national-cancer- institute Additional coverage: MedicalHealthNews.net http://www.medicalhealthnews.net/ramon-parsons-awarded-outstanding-investigator-award-from-the-national- cancer-institute Hindustan Times – November 30 HTLS 2017: Cut Down On Animal Fat, Red Meat, And Sugar To Prevent Cancer Cancer kills 700,000 people every year and 30 percent of these deaths can be prevented by simple lifestyle changes and early detection, said Ash Tewari, MBBS, MCh, professor and system chair of urology at the Icahn School of Medicine at Mount Sinai at the 15th Hindustan Times Leadership Summit. Dr. Tewari set the tone for the session, titled “How to Beat Cancer”, with the suggestion that India should open itself to a more honest conversation on the disease. “If you begin the fight early on when it’s possible to zap the cells, the cancer is treatable… but if you wait for the symptoms, the fight gets difficult,” Dr. Tewari said. More than 1.4 million people in India are diagnosed with cancer every year. Breast and cervical cancers in women and lung and oral cancers in men are the leading forms of the disease. Lifestyle changes, the experts agreed, play a major role in preventing cancer. Dr. Tewari, an expert in robotic surgery of prostate and urinary cancers, advised that people should be more careful about inflammations. “For instance, a liver inflammation can lead to cancer. Any inflammation or a lump that is left unattended can grow into a cancer. Inflammation can be provoked by chronic stress,” he said. - Ashutosh Tewari, MBBS, MCh, Professor, System Chair, Urology, Icahn School of Medicine at Mount Sinai Learn more: http://www.hindustantimes.com/htls/htls-2017-cut-down-on-animal-fat-red-meat-and-sugar-to-prevent-cancer-say- specialists/story-bvTPKbWQbKKb7DrAFB4CeO.html Additional coverage: MedicalHealthNews.net http://www.medicalhealthnews.net/htls-2017-cut-down-on-animal-fat-red-meat-and-sugar-to-prevent-cancer-say- specialists First Post http://www.firstpost.com/india/hindustan-times-leadership-summit-2017-narendra-modi-set-to-headline-stellar-line-up-of- movers-and-shakers-4233953.html News 18 http://www.news18.com/news/india/india-needs-to-invest-in-its-cancer-care-infrastructure-to-bring-down-deaths-scientists- 1591463.html Broadway World – November 29 One-Man Show To Tackle Tourette Syndrome In The Elephant In Every Room I Enter At Mount Sinai The Icahn School of Medicine at Mount Sinai will host actor Gardiner Comfort’s The Elephant In Every Room I Enter, solo performance on living with Tourette’s syndrome on Thursday, November 30th from 5-6:30pm. The performance is part of the Alexander Richman, MD and Charlotte Yudell, MD Seminar Series on Humanism and Ethics in Medicine. His performance will be followed by a conversation led by his physician, Barbara Coffey, MD, MS, professor of psychiatry and chief of the Tics and Tourette’s clinical and research program at the Icahn School of Medicine at Mount Sinai. - Barbara Coffey, MD, MS, Professor, Psychiatry, Chief, Tics and Tourette’s Clinical and Research Program, Icahn School of Medicine at Mount Sinai Learn more: https://www.broadwayworld.com/article/One-Man-Show-to-Tackle-Tourette-Syndrome-in-THE-ELEPHANT-IN-EVERY- ROOM-I-ENTER-at-Mount-Sinai-20171129 WCBS NY Radio – November 28 Drug Trials To Help Eye Stroke Victims Jeff Markowitz hopes to regain the vision he’s lost. He had a stroke in the eye which happens when blood vessels supplying nutrients and oxygen to the optic nerve get blocked. It can cause sudden vision loss and sometimes blindness. With no effective treatments available, Jeff enrolled in a clinical trial at the New York Eye and Ear Infirmary of Mount Sinai testing a new experimental drug. "We believe that this molecule has the ability to stop the cascade of events which leads to cell death, actually preserve vision, and possibly restore some of the vision that's been lost," said Rudrani Banik, MD, associate professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and an ophthalmologist at the New York Eye and Ear Infirmary of Mount Sinai. The drug called QPI-1007 is injected into the eye three times over six months. Dr. Banik says it's critical to start treatment within two weeks of symptoms. "We think there is a window of time in which we should get the drug to the patient," he said. Jeff doesn't know yet if he's getting the actual drug or a placebo since the study is ongoing. But so far, he says he is seeing better. - Rudrani Banik, MD, Associate Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Ophthalmologist, The New York Eye and Ear Infirmary of Mount Sinai Learn more: http://mms.tveyes.com/PlaybackPortal.aspx?SavedEditID=2506baff-3f04-4db5-b503-1d4b2297c579 Additional coverage: CBS New York – Dr. Max Gomez http://newyork.cbslocal.com/2017/11/30/eye-strokes-experimental-treatment/ Politico New York – November 30 Coming Attractions — Dan Goldberg Ashish Atreja, MD, MPH, assistant professor of medicine and gastroenterology at the Icahn School of Medicine at Mount Sinai, director of Sinai AppLab, and chief technology, innovation, and engagement officer at The Mount Sinai Hospital, is leading a conference on December 4-5. - Ashish Atreja, MD, MPH, Assistant Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Director, Sinai AppLab, Chief Technology, Innovation and Engagement Officer, The Mount Sinai Hospital Learn more: https://www.politico.com/states/new-york/newsletters/politico-new-york-health-care/2017/11/30/vullo-sues-feds-for-575- million-012227 Food Allergy Research & Education – November 30 20th Anniversary Food Allergy Ball Honorees The 20th Anniversary Food Allergy Ball will be held Monday, December 4 in New York at the Pierre Hotel. To commemorate the 20th anniversary of this event, the evening will honor “20 for 20,” a special tribute to the pioneers who have made a lasting impact in the food allergy community and have contributed to 20 years of progress in food allergy action, research, education and advocacy. Those being honored include Hugh Sampson, MD, professor of pediatrics, allergy and immunology, dean for translational biomedical research, and director of the Elliot and Roslyn Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai, and Scott Sicherer, MD, professor of pediatrics, allergy and immunology at the Icahn School of Medicine at Mount Sinai. - Scott Sicherer, MD, Professor, Pediatrics, Allergy and Immunology, Icahn School of Medicine at Mount Sinai - Hugh Sampson, MD, Professor, Pediatrics, Allergy and Immunology, Dean, Translational Biomedical Research, Director, Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai Learn more: https://www.foodallergy.org/about-fare/blog/20th-anniversary-food-allergy-ball-honorees-part-1 Science News – November 29 Scientists Are Seeking New Strategies To Fight Multiple Sclerosis — Ashley Yeager James Davis used to be an avid outdoorsman. Today, the 48 year old from Albuquerque barely gets out of bed. He has the most severe form of multiple sclerosis, known as primary progressive MS, a worsening disease that destroys the central nervous system. Davis hoped life might improve when he was chosen in 2012 to participate in a clinical trial of a drug called ocrelizumab. The drug offered a first sliver of hope for patients waiting for a cure, or at least something to slow down the disease’s staggering march. Ocrelizumab was heralded as a breakthrough, and in March, the US Food and Drug Administration approved it as a treatment for primary progressive and relapsing- remitting MS. “We finally have an approved therapy for primary progressive MS,” said Fred Lublin, MD, Saunders family professor of neurology at the Icahn School of Medicine at Mount Sinai and director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai Hospital. The first drug to treat relapsing-remitting MS came on the market in 1993, Dr. Lublin notes. Now, nearly a quarter century later, there’s something that